Guangzhou Baiyunshan Pharmaceutical Holdings Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Hong Li
Algemeen directeur
CN¥1.5m
Totale compensatie
| Percentage CEO-salaris | 30.6% |
| Dienstverband CEO | 7.4yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 7.4yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23
Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥3b |
| Jun 30 2024 | n/a | n/a | CN¥4b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥2m | CN¥471k | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥460k | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥2m | CN¥456k | CN¥4b |
| Sep 30 2021 | n/a | n/a | CN¥4b |
| Jun 30 2021 | n/a | n/a | CN¥4b |
| Mar 31 2021 | n/a | n/a | CN¥3b |
| Dec 31 2020 | CN¥1m | CN¥442k | CN¥3b |
| Sep 30 2020 | n/a | n/a | CN¥3b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥3b |
| Dec 31 2019 | CN¥1m | CN¥428k | CN¥3b |
| Sep 30 2019 | n/a | n/a | CN¥3b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥4b |
| Dec 31 2018 | CN¥1m | CN¥382k | CN¥3b |
Compensatie versus markt: De totale vergoeding ($USD 216.11K ) Hong } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 640.18K ).
Compensatie versus inkomsten: De vergoeding van Hong is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Hong Li (57 yo)
7.4yrs
Tenure
CN¥1,539,030
Compensatie
Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| GM & Executive Director | 7.4yrs | CN¥1.54m | geen gegevens | |
| Executive Vice Chairman | 12.2yrs | geen gegevens | geen gegevens | |
| Executive Vice Chairman | 4.8yrs | geen gegevens | geen gegevens | |
| Deputy GM & Executive Director | 9.8yrs | CN¥1.57m | geen gegevens | |
| Executive Director | no data | geen gegevens | geen gegevens | |
| Deputy GM & Director of Business Administration Department | 5.3yrs | CN¥1.41m | geen gegevens | |
| Secretary | 7.6yrs | CN¥1.24m | geen gegevens |
7.4yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 874 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| GM & Executive Director | 6.4yrs | CN¥1.54m | geen gegevens | |
| Executive Vice Chairman | 12.2yrs | geen gegevens | geen gegevens | |
| Executive Vice Chairman | 4.8yrs | geen gegevens | geen gegevens | |
| Deputy GM & Executive Director | 14.4yrs | CN¥1.57m | geen gegevens | |
| Executive Director | 10.8yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 1.5yrs | CN¥50.00k | geen gegevens | |
| Chairman of the Supervisory Board | 5.2yrs | geen gegevens | geen gegevens | |
| Supervisor | 4.8yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 4.4yrs | CN¥120.00k | geen gegevens | |
| Independent Non-Executive Director | 4.4yrs | CN¥120.00k | geen gegevens | |
| Supervisor | 3.4yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 1.5yrs | CN¥70.00k | geen gegevens |
4.8yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 874 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).